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1. Introduction  
Although their functions in tumour development and progression are not well understood, 
several secreted and membrane-associated mucins have proven to be valuable diagnostic 
and prognostic markers in human cancer and many of these are targets for cancer vaccines 
and therapies (Singh et al., 2008; Chauhan et al., 2009; Kufe, 2009). Podocalyxin-like protein 
1 (podocalyxin, gene name PODXL) is a member of the CD34 family of sialomucins. 
Podocalyxin (PC), also called PCLP1, gp135, MEP21, and thrombomucin, is a single-pass 
type I transmembrane protein primarily expressed by vascular endothelia, specialized 
kidney epithelial cells called podocytes, and a limited set of hematopoietic progenitor cells 
in adult mice and humans (Nielsen & McNagny, 2009b). Expression of PC has also been 
noted on the luminal face of kidney tubule cells, breast and ductal lumens, oviductal 
luminal cells, mesothelial cells and neurons in normal mammalian tissues. Polymorphisms 
and inappropriate or increased expression of PC is linked to several human cancers 
including germ-line cancers, several carcinomas, malignant astrocytoma and leukemia. In 
many of these cancers, detection of high levels of PC expression is associated with high-
grade, aggressive tumours, increased risk of metastases and poor prognosis. In this review, 
we will examine the known and proposed functions of PC in normal (adult and embryonic) 
and cancerous cells, the molecular mechanisms regulating these functions, and potential 
applications of PC as a molecular marker in the diagnosis, prognosis and treatment of 
cancer. 
2. Podocalyxin expression and normal function in mammals 
2.1 Podocalyxin has an essential role in the development and function of the kidney 
glomerulus  
PC is named for its expression on specialized kidney epithelial cells called podocytes. On 
these cells, PC is required for the development of the foot process that, together with 
fenestrated vascular endothelia, form the filtration apparatus of the glomerulus (reviewed in 
Nielsen & McNagny, 2009b). Unlike vascular and hematopoietic tissues where other 
members of the CD34 family are co-expressed, PC is the only CD34-family sialomucin 
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expressed on podocytes and therefore serves a non-redundant function in podocyte 
development. Germ-line deletion of Podxl in mice results in anuria and death within 24 
hours of birth due to the failure of embryonic podocytes to undergo appropriate 
morphogenesis and form foot processes - one of the most potent mucin-dependent knockout 
phenotypes described (Doyonnas et al., 2001).  
Although many tissue types and cell lineages express PC during mouse embryogenesis 
(and presumably human), PC’s only essential function identified so far is the formation of 
the glomerular filtration apparatus of the kidney. However, we are beginning to discover 
more subtle roles for PC in the development, morphogenesis, polarization and motility of 
cells that form the lumen of tubules and ducts (or boundary elements in tissues) including 
kidney tubules, ovary ducts, mammary ducts and vascular lumens. For example, germ-
line deletion of Podxl in mice causes a delay in the formation of lumens between adjacent 
endothelial cells of the developing aorta (Strilic et al., 2009) and reduces the adhesion of 
the mesothelia lining of the gut surface mesothelia to the umbilicus during embryogenesis 
(Doyonnas et al., 2001). From these and other embryonic analyses we have developed the 
concept that podocalyxin acts a general anti-adhesive that aids in the demarcation of 
tissue boundaries (McNagny et al., 1997; Doyonnas et al., 2001). PC expression is also 
required for efficient neurite outgrowth and branching in the developing brain (Vitureira 
et al., 2005, 2010). Despite these subtle developmental delays or abnormalities, in all 
tissues we have examined so far, save the kidney, Podxl-/- mouse neonates appear to be 
remarkably normal. 
In adult mice and humans, PC is primarily restricted to vascular endothelia, kidney 
podocytes and a subset of hematopoietic stem cells.  In addition, PC expression has also 
been reported on some mature blood types including mouse “stress” erythroid 
progenitors (and anemia-induced erythroblasts) (Doyonnas et al., 2005; Sathyanarayana 
et al., 2007; Maltby et al., 2009) and activated rat platelets (Miettinen et al., 1999). 
Although others and we have proposed a role for PC (and the CD34 antigen) in 
facilitating the trafficking of hematopoietic progenitors cells to the bone marrow (BM) as 
well as more mature blood cells from the BM or periphery to sites of inflammation 
(Nielsen & McNagny, 2008, 2009a, 2009b), the function of PC expression on normal 
hematopoietic cells remains enigmatic.  
In summary, although PC has a critical role in kidney development, PC appears to be 
dispensable for the normal development of other tissues we have examined including 
vascular endothelia, breast duct epithelia and hematopoietic tissues. However, after 
increasingly more detailed analyses, we have also found that PC has subtle roles in these 
tissues under conditions of tissue remodeling and development that may have 
consequences in disease pathogenesis (unpublished observations).  
2.2 Transcriptional regulation of PODXL expression 
The regulation of PODXL expression is modulated by several transcription factors, 
epigenetic methylation of CpG islands in the PODXL promoter and by expression of micro 
RNA (miR-199a2). Depending on the cell lineage and disease state, PODXL expression can 
be induced by Sp1 (specificity protein 1) and Wilms’ tumour suppressor protein 1 (WT1). 
The PODXL promoter contains multiple binding sites for Sp1 and there is evidence of direct 
binding of WT1 to the PODXL promoter (Palmer et al., 2001; Butta et al., 2006). While Sp1 is 
expressed in many cell types and has many targets in the human genome, Sp1 is 
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upregulated in many cancers including epithelial carcinomas (reviewed in Li & Davie, 
2010). WT1 is primarily expressed in developing kidney and in the podocytes of the 
glomerulus in normal kidney. However, WT1 is overexpressed in cancers of the kidney, 
lung and breast and in acute leukemia and myelodysplastic syndromes. Thus, both Sp1 and 
WT1 may influence the expression of PODXL in cancers. 
Adult erythroid cells express PC in response to anemic stress via erythropoietin receptor 
(EpoR)-dependent activation of the signal transducer and activator of transcription 5 
(STAT5) (Sathyanarayana et al., 2007). Although PODXL expression via STAT5 has not been 
demonstrated in other cell types, STAT5 activation can be induced in epithelial cells by a 
variety of mechanisms. For example, with respect to the pathogenesis of carcinomas 
(especially prostate and breast cancers) STAT5 activation downstream of the prolactin 
receptor activation is one possible route to enhanced PC expression (Jacobson et al., 2010). 
Transcriptional repressors of PODXL include the ubiquitously expressed tumour 
suppressor transcription factor p53 (TP53) and the integrin-associated adaptor protein 
PINCH1 (LIMS1) (Stanhope-Baker et al., 2004; Wang et al., 2011). PINCH1 is normally 
associated with focal adhesion complexes in podocytes but becomes dissociated from 
these in response to transforming growth factor beta (TGF) stimulation (Wang et al., 
2011). PINCH1 then enters the nucleus and antagonizes WT1 transcriptional activation of 
PODXL (Wang et al., 2011). Since TGF can induce PODXL expression in a human lung 
adenocarcinoma cell line (see §3.5.1) (Meng et al., 2011), the role of TGF and PINCH1 in 
the regulation of PODXL expression may be specific to podocytes (or normal, adherent 
epithelia). Finally, PODXL is a target for miR-199a2, a micro RNA that is normally 
expressed in epithelial cells of many tissues (Cheung et al., 2011). miR-199a2 targets 
(represses) a collection of transcripts and has a putative role as a tumour suppressor in 
several human cancers (see §3.7.2). 
3. Podocalyxin is a diagnostic marker and prognostic indicator in cancer 
Within the last 5-7 years, retrospective analysis of tumour tissue archives by histology, 
protein and transcript expression analyses have identified increased PC expression or 
PODXL gene polymorphisms in several human cancers. In this section, we will outline what 
is known of PC expression patterns in human cancers including epithelial carcinomas 
(kidney, breast, thyroid, lung, ovarian, prostate and gastrointestinal cancer), germ-cell 
tumours (testicular cancer), astrocytomas (brain cancer) and leukemia (Table 1). In general, 
in studies where PC expression has been correlated with tumour behaviour and patient 
outcome data, PC expression in primary tumour cells is associated with increased tumour 
aggressiveness, risk of distant metastases and poor prognosis. Mechanistic studies using 
human cancer cell lines suggest that PC expression in tumour cells is not just merely 
correlative with aggressiveness, but may have a direct contribution to tumour progression, 
survival and metastases. In addition to the potential this wealth of data offers for the 
development of PC-targeted adjuvant treatments for systemic cancer, these findings and 
accompanying mechanistic studies provide insights into the molecular mechanisms of 
tumour progression and metastases. While it is clear that there remain many technical 
challenges for the development of PC-targeted cancer treatments, implementation of 
clinically beneficial diagnostics is feasible and compatible with existing technology and 
methods, requiring only a concerted validation effort.  
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Review Section (§) 
Primary Tissue  
Podocalyxin expression profile Diagnostic & Prognostic 
Significance 
§3.1.1 
Kidney   
(Renal cell 
carcinoma) 
 PC protein expression 4-fold higher in cancerous cells of 
rare subset of RCC tumours (~10%)  
 PC expression in primary RCC correlates with risk of 
metastasis and poor patient outcome. 
Hazard ratios  (HR) (PC+ vs. PC- RCC primary tumors)  
HR = 3.6 (metastasis-free survival)  
HR = 7.5 (disease-specific survival) 
(Hsu et al., 2010) 
 PC expression in tumor 
cells correlates with 
increased risk of aggressive 
tumor phenotype, and is an 
independent predictor of 
distant metastases and 
poor prognosis 
§3.1.2 
Kidney  
(Nephroblastoma) 
 Higher PC transcript expression  ( 1.5 fold) in more 
aggressive anaplastic (advanced grade) compared to low 
grade nephroblastoma 
(Stanhope-Baker et al., 2004) 
 Diagnostic marker 
(transcript) of anaplastic 
grade nephroblastoma 
§3.2 
Breast carcinoma 
 High PC protein expression in rare “node-negative” 
subset of breast carcinoma (~6%) 
 PC overexpression in primary breast tumours associated 
with increased relative risk of poor outcome (RR = 8.45) 
(Somasiri et al., 2004) 
 PC expression in tumor 
cells correlates with 
increased risk of aggressive 
tumor phenotype, and is an 
independent predictor of 
distant metastases and 
poor prognosis 
§3.3 
Ovarian carcinoma 
 High expression of PC on tumour cells in 67% of all 
ovarian epithelial tumours and 87% of high-grade serous 
epithelial ovarian carcinoma  
 PC cytoplasmic expression not associated with disease-
outcome in high-grade serous ovarian tumours, but cell 
surface expression of PC is an independent predictor of 
poor patient outcome with HR ~ 1.6 (compared to PC-
negative high-grade serous ovarian tumor) 
(Cipollone et al, submitted) 
 Prognostic marker of poor 
outcome in high-grade 
serous ovarian cancer 
when PC overexpression is 
cell surface localized 
 
§3.4 
Thyroid carcinoma 
 High expression of PC protein common (~52% cases) in 
undifferentiated thyroid carcinoma (UTC) subtype but not 
detected in normal thyroid epithelia or other thyroid 
cancer cells (Yasuoka et al., 2008) 
 Diagnostic and staging 
marker of undifferentiated 
thyroid carcinoma 
§3.5 
Lung  
(small-cell lung 
carcinoma) 
 PC protein expression detected in tumour cells in majority 
(~87.5%) in small-cell lung carcinoma (SCLC) 
(Koch et al., 2008) 
 Diagnostic marker (tissue 
biopsy) 
§3.6 
Prostate carcinoma 
 PODXL germ-line polymorphism and SNP are associated 
with increased risk of developing prostate cancer with an 
aggressive tumor. 
In-frame single or double deletion polymorphism in exon 
1 associated with increased risk of prostate cancer 
Odds ratio (OR) = 2.14-2.58 (all prostate cancer) 
OR = 3.04-4.42 (aggressive disease) 
SNP (G340A) resulting in missense mutation associated 
with increased risk of prostate cancer 
OR  = 1.48 (all prostate cancer) 
(Neville et al., 2002) 
 Possible increased PC expression in metastatic tumor but 
not primary prostate tumours (Fig. 5) 
(Yu et al., 2004; Chandran et al., 2007) 
 Genetic marker of prostate 
cancer risk 
 High expression of PC a 
potential prognostic 
marker of tumour 
aggressiveness and 
metastases 
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Review Section (§) 
Primary Tissue  
Podocalyxin expression profile Diagnostic & Prognostic 
Significance 
§3.7 
Testicular 
(germ cell tumour) 
 PC antigens (GCTM-2, TRA-1-60/81) detected in serum of 
testicular cancer patients (35-75% NSGCT cases) 
(Schopperle et al., 2003) 
 PODXL-targeting miR-199a downregulated in testicular 
cancer (Cheung et al., 2011) 
 Potential serum marker for 
testicular cancer 
 PC potentially equally or 
more robust marker of 
testicular cancer compared 
to  
-fetoprotein or chorionic 
gonadotrophin 
§3.8.1 
Liver 
(hepatocellular 
carcinoma (HCC)) 
 High expression of PC protein detected in sinusoidal 
endothelial associated with HCC but not normal adjacent 
tissue or cirrhotic lesions  
(Chen et al., 2004; Heukamp et al., 2006) 
 Differential diagnosis of 
HCC vs. cirrhotic lesions 
(tissue biopsy) 
§3.8.2 
Pancreatic ductal 
adenocarcinoma 
 PC protein expressed in primary tumours of 42% 
pancreatic ductal adenocarcinoma (PDAC) and 30% 
ampullary ductal carcinoma but rarely in other primary 
tumours of GI origin  
(e.g., liver, colon, esophagus)  
 High PC expression more often detected in high-grade 
PDAC (53% Grade 3, 48% Grade 2 and 18% Grade 1)  
(Ney et al., 2007) 
 Possible identification of 
primary tissue of 
metastatic tumours from a 
suspected GI source  
§3.8.3 
Colon carcinoma 
 PC protein and peptides detected in media and lysate of 
colon carcinoma cell lines. Expression not yet determined 
in colon cancer primary tumours.  
(Thomas et al., 2009) 
 Potential serum marker for 
colon cancer 
§3.9 
Hematopoietic 
 PC protein expression commonly detected (77-87% cases) 
in diffuse pattern (immunohistology) in formalin-fixed 
bone marrow biopsy in majority cases of AML, ALL and 
myeloid sarcoma (Kelley et al., 2005). 
 Cell surface expression in 20% AML from fresh blood or 
bone marrow samples (flow cytometry)  
 (Riccioni et al., 2006). 
 Potential diagnostic marker 
(tissue biopsy), however 
significance to disease 
phenotype and outcome 
not known 
 Potential surface marker of 
AML blasts in peripheral 
blood 
§3.10 
Brain (astrocytoma)
 High PC protein and transcript expression in ~50% cases 
of high-grade malignant astrocytomas (anaplastic 
astrocytoma and glioblastoma) but not low-grade 
astrocytic tumours (Hayatsu et al., 2008). 
 Diagnostic marker of high 
grade/anaplastic 
astrocytoma 
Table 1.  Summary of podocalyxin expression profiles in human cancers. 
3.1 Kidney cancer 
3.1.1 Renal cell carcinoma 
Renal cell carcinoma (RCC), which accounts for 85% of renal cancers, originates from 
epithelial cells of the renal tubules (Cohen & McGovern, 2005). In a retrospective study, PC 
protein expression was examined in a collection of 303 formalin-fixed, paraffin-embedded 
RCC tumours (Hsu et al., 2010). Of these, 29 tumour specimens (9.6%) were found to express 
PC protein in cancerous cells (4-fold over non-expressors) (Hsu et al., 2010). In contrast, in 
normal kidney and the majority of RCC patient tumours, PC is only detected in the 
glomerulus and vascular endothelia (Hsu et al., 2010). Patient outcome data showed that 
PC-positive RCC tumours were much more likely to be high-grade, advanced-stage 
tumours (Hsu et al., 2010). Importantly, patients with PC-positive RCC also had decreased  
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disease-specific and metastasis-free survival and PC-positive RCC tumours (stage I-III) were 
more likely to result in distant metastases (i.e., non-lymph node sites) (Hsu et al., 2010). 
These findings suggest that PC expression in primary RCC tumours is a strong and 
independent predictor of distant metastasis and poor prognosis (Hsu et al., 2010). Thus, by 
identifying a rare, high-risk RCC sub-type, evaluation of PC expression has clear potential 
diagnostic and prognostic value.  
3.1.2 Wilms’ tumor (Nephroblastoma) 
Wilms’ tumour, or nephroblastoma, the most common pediatric kidney cancer, has a unique 
histological presentation indicative of aberrant or incomplete kidney development during 
embryogenesis (Huff, 2011). Unlike most of the cancers discussed in this review, PC 
expression (transcript) is significantly reduced in 64 patient nephroblastoma samples (relative 
mean 0.29) compared to pooled normal fetal kidney (Stanhope-Baker et al., 2004). Although 
WT1 is a positive regulator of PODXL expression (Palmer et al., 2001), and loss of WT1 
expression is associated with some Wilms’ tumours, there was no evidence of a correlation 
between PODXL and WT1 expression in this study (Stanhope-Baker et al., 2004). However, 
perhaps of diagnostic value, this same study showed that PODXL expression was increased 
in more aggressive, anaplastic tumours compared to 40 non-anaplastic tumors (Stanhope-
Baker et al., 2004). Notably, functional loss of p53 is associated with the most aggressive, 
anaplastic nephroblastomas with poor prognosis. As p53 negatively regulates PODXL 
expression (Stanhope-Baker et al., 2004), enhanced PODXL expression in anaplastic 
nephroblastomas may be explained directly by this genetic pathway. Although more study 
is required to know if enhanced PODXL expression in anaplastic nephroblastoma has a 
direct role in promoting tumour aggressiveness, expression of PODXL in nephroblastoma 
may be useful as a marker of poorly differentiated, anaplastic tumours. 
3.2 Breast carcinoma 
3.2.1 Expression of podocalyxin is an independent predictor of poor outcome in 
invasive breast carcinoma 
In normal human breast tissue, expression of PC protein is relatively low and restricted to 
the apical face of the luminal duct epithelia and, as in most tissues, PC also marks the lumen 
of vascular endothelia in the breast (Somasiri et al., 2004). However, in a survey of tissue 
microarray constructed from 272 primary tumour samples from patients with locally 
invasive breast cancer, high expression of PC protein was detected in a small subset (6%) of 
invasive breast carcinomas (Somasiri et al., 2004). Notably, PC-positive primary tumours 
were associated with significantly higher risk of poor outcome (decreased disease-specific 
survival) compared to patients with tumours expressing little or no PC (Somasiri et al., 
2004). PC-positive tumours were not significantly different in histological classification, size 
or risk of lymph node metastasis. However, PC expressing tumours were more likely to 
present at an advanced tumour grade, express p53, and be negative for estrogen receptor 
(ER) (ESR1) and HER-2 (ERBB2) (Somasiri et al., 2004). These data reveal that high 
expression of PC in primary, locally invasive breast carcinoma is a strong and independent 
predictor of poor outcome (Somasiri et al., 2004). As with its detection of rare RCC subsets, 
evaluation of PC expression in primary breast carcinomas may have immediate diagnostic 
and prognostic value in guiding treatment or surveillance strategies in breast cancer. In 
addition, detailed profiling of PC-tumours may provide a deeper understanding of tumour 
progression mechanisms. Related to these efforts, in the next section we discuss some of the 
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molecular mechanisms that underlay PC’s role in promoting progression of invasive breast 
cancer to metastatic breast carcinoma.  
3.2.2 Podocalyxin regulates breast cancer tumour cell invasiveness and migration in 
vitro 
In order to gain insight into the biological role of PC in breast cancer, we, as well as other 
investigators, have surveyed the expression of PODXL and its intracellular ligands, NHERF-
1 and -2, in human breast cancer cell lines and examined the effects of altering its expression 
on the behavior of these cells in vitro and in vivo.  Recent microarray analysis of a collection 
of 50 human breast cancer cell lines revealed a wide range of expression of PODXL, NHERF-
1 (SLC9A3R1) and NHERF-2 (SLC9A3R2) transcripts (Kao et al., 2009) (Fig. 1). PODXL tends 
to be highly expressed in estrogen receptor- and progesterone receptor (PR)-negative (ER-
/PR-) basal-like breast cancer lines. Conversely, high NHERF-1 and NHERF-2 expression 
correlates with luminal-type, ER+ breast cancers. MCF7 cells are a line of luminal-like breast 
epithelial cells (Neve et al., 2006; Kao et al., 2009) obtained by pleural effusion (i.e., lung 
metastases) of a patient with metastatic invasive ductal adenocarcinoma (ER+/PR+)(Soule et 
al., 1973). Relative to other breast cancer cell lines, MCF7 expresses low-moderate levels of 
endogenous PODXL transcripts and high levels of NHERF-1 (and low to moderate 
expression of NHERF-2) (Kao et al., 2009) (Fig. 1). MDA.MB.231 cells, which express high 
levels of endogenous PODXL, are a basal B-subtype breast cancer cell line derived from 
pleural effusion of human metastatic breast adenocarcinoma (Kao et al., 2009) (Fig. 1). In 
contrast to MCF7 cells, MDA.MB.231 are ER-/PR- and have a highly invasive phenotype in 
in vitro assays and in vivo xenograft models (Lacroix and Leclercq, 2004; Neve et al., 2006). 
By overexpressing exogenous PC and structural mutants in MCF7 cells or by suppressing 
endogenous PC in MDA.MB.231 cells using RNA-interference (RNAi) methods, we (and 
others) have found that PC promotes a more aggressive, invasive phenotype in vitro and in 
vivo (Somasiri et al., 2004; Sizemore et al., 2007). In addition, our preliminary results 
corroborate a role for PC in breast cancer invasion since suppression of endogenous PODXL 
in MDA.MB.231 impairs serum-dependent migration in vitro (Turvey & McColl, 
unpublished observations). We are currently working to determine if silencing PODXL 
expression down regulates invasion-associated adhesion molecules and matrix proteinases 
and how loss of PODXL alters the morphology and cytoskeletal dynamics in MDA.MB.231. 
 
 
Fig. 1. Transcript expression levels of PODXL, NHERF1 and NHERF2 in a collection of 
human breast cancer cell lines. Arrows indicate the luminal-like MCF7 and basal (B)-like 
MDA.MB.231 breast cancer cell lines commonly used in the study of PC function. The 
transcript expression heat map was generated from meta-analysis of publically available 
microarray gene expression profiles of human breast cancer cell lines (Kao et al., 2009) using 
Gene Cluster 3.0 and Java TreeView. 
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3.2.3 Podocalyxin modulates EMT-independent breast cancer progression and 
metastatic potential 
Epithelial-to-mesenchymal transition (EMT) is an important paradigm in the understanding 
of tumor progression to systemic, metastatic cancer (discussed in more detail in §3.5.1). 
However, EMT is not an obligate pathway to metastases (Wicki et al., 2006), and invasive 
ductal breast carcinomas, which form the great majority of locally invasive breast lesions, 
retain epithelial characteristics and epithelial differentiation markers (Cleton-Jansen, 2002; 
Sarrio et al., 2008). Thus, a better understanding of EMT-independent mechanisms of 
tumour invasion and metastasis is critical for developing therapeutic strategies in ductal 
breast carcinoma in particular, but also other cancers in general.  
By expressing exogenous PODXL in MCF7 cells, we have found that PC promotes altered 
morphogenesis, loss of adhesion and impaired tumour cell aggregation in 3D spheroid 
cultures (Graves and Roskelley, manuscript in preparation).  Importantly, altered adhesion is 
not associated with disruption of cell-cell junctions, impaired expression or re-localization of 
cell-cell junction regulators (e.g., E-cadherin, -catenin, ZO-1) or, disruption of extra-cellular 
matrix (ECM) adhesion complexes (e.g., 1-integrin, activated focal adhesion kinase (FAK)). 
Rather, expression of PC in polarized cells enhances the exclusion of 1-integrins from the free, 
apical surface of MCF7 and recruits F-actin from the basolateral ECM-adhesion complexes to 
an expanded apical membrane domain. We hypothesize that PC-mediated redistribution of F-
actin and other cortical actin components weakens adhesion of the basolateral membrane 
domain to ECM. Moreover, when single cells are shed from the epithelial sheets, PC is 
redistributed in a global pattern that blocks homotypic adhesion. Expression of PC on shed, 
single cells may also promote chemotaxis, enhance adhesion-free survival or participate in the 
homing to distant tissue sites (Fig. 2). Thus, while PC expression in some epithelial tissues may 
help to define the apical domain and reinforce polarization, dysregulated mistargetting or 
overexpression of PC disrupts normal tissue architecture of epithelial sheets and spheroids 
and may promote invasive and metastatic characteristics. 
 
 
Fig. 2. Podocalyxin expression defines the apical domain of polarized epithelia but promotes 
non-EMT loss of adhesion and shedding when overexpressed. 
Finally, to gain some insight into the in vivo function of PC in the growth, local invasion and 
metastatic potential of human breast cancers, we have used tumor xenograft models. In 
preliminary experiments, sub-cutaneous transplantation of MCF7 or PC-overexpressing 
MCF7 cells into immunodeficient mice (Rag2M) suggests that expression of high levels of 
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PC enhance tumour growth and density (Graves and Roskelley, manuscript in preparation). 
In addition, although the PC–positive MDA.MB.231 cell line forms lung tumors in NOD-
SCID Il2r -/- (NSG) mice 6-8 weeks after intravenous injection, PC-deficient MDA.MB.231 
cells fail to form lung tumours (Turvey and McColl, unpublished observations). Because 
equal numbers of PC-positive and PC-negative MDA.MB.231 tumor cells appear in the 
pulmonary parenchyma at early time points (3-14 days), we hypothesize that PC promotes 
survival in recipient lung tissue (Snyder, Hughes and McNagny, unpublished observations). 
We are continuing to use these models, and orthotopic mammary fat pad transplant breast 
tumour models, to fully characterize PC’s role in breast tumour invasion and metastases. In 
summary, the data suggest PC plays a key role in enhancing breast carcinoma growth and 
invasiveness in vivo. 
3.3 Ovarian carcinoma 
Ovarian cancer remains the most lethal gynecological cancers and, like most epithelial 
carcinomas, systemic spread generally has a poor prognosis since there are currently no 
curative interventional therapies. PC is expressed in normal mesothelia-derived tissues that 
encase the ovaries and make up the free luminal surface of cells that line the oviducts and 
endometrium (Cipollone and Roskelley, manuscript submitted). In addition, PC protein is 
detectable in the tumor cells of approximately two-thirds of human ovarian carcinoma 
cases. Although the mere presence of PC protein in ovarian carcinomas does not correlate 
with disease outcome, expression of PC on the cell surface (as opposed to intracellular 
localization) is predictive of poor outcome for high-grade serous ovarian carcinoma, 87% of 
which express significant amounts of the mucin.  
As with breast cancer cell lines, PC expression in ovarian cancer lines is variable (Cipollone 
and Roskelley, ibid). To evaluate PC’s molecular functions in ovarian carcinoma, we ectopically 
expressed PC in the serous carcinoma-derived cell line (OVCAR-3) originally derived from 
malignant ascites (Hamilton et al., 1983). OVCAR-3 cells express epithelial differentiation 
markers, form well-structured adherent epithelial sheets in culture, and are generally non-
invasive and have low motility in vitro (Comamala et al., 2011). Forced expression of PC in 
OVCAR-3 cells reduced in vitro adhesion to extracellular matrices including; mesothelial-cell 
layers, immobilized 1-integrin antibodies and fibronectin. As with other epithelial cells, 
exogenously expressed PC is preferentially localized to the apical free surface of OVCAR-3 cell 
layers in 2D culture and spheroids in 3D culture. As observed in MCF7 cells, PC excludes 1-
integrin from free apical domains. Thus, when expressed at the cell surface, PC may act as an 
anti-adhesin in serous ovarian carcinoma by sterically masking integrin-extracellular matrix 
interactions, and, by promoting cortical cytoskeletal rearrangements that weaken adhesion to 
ECM. This PC-induced morphogenesis may be of critical importance to ovarian carcinoma 
progression, as these tumors very often metastasize after small nodules are shed, in an anti-
adhesive (non-EMT dependent) fashion, into the abdominopelvic cavity. Thus, while PC-
driven non-EMT shedding and migration may be rare in some epithelial cancers (breast and 
renal), PC expression may be a common, and critically important molecular mechanism 
driving tumour metastasis in high-grade serous ovarian carcinoma. 
3.4 Thyroid carcinoma 
Thyroid carcinomas (non-lymphoma, squamous cell or sarcoma) are classified according to 
histological characteristics and origin. The most common “differentiated” subtypes 
(papillary and follicular) are highly treatable and responsive to therapy. The medullary and 
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undifferentiated (anaplastic) sub-types, although more rare, have a less favorable prognosis. 
Although PC is normally absent on thyroid epithelia and is not detected in well-
differentiated thyroid carcinoma tumour subtypes or squamous cell carcinoma (thyroid), in 
immunohistological analyses of 238 thyroid tumours, PC was detected on tumours of over 
half the cases (n=69) of undifferentiated thyroid carcinoma (UTC). In addition, in cases 
where the thyroid tumours have a mixed histological type (UTC adjacent to differentiated 
tumour cells), PC was detected only on cells with UTC phenotype (Yasuoka et al., 2008). We 
note that the pattern of PC expression on thyroid carcinoma and small-cell lung carcinoma 
(§3.5) (correlates with a “de-differentiated” tumour phenotype consistent with an EMT 
transformation. Thus, although PC may not be sufficient to drive EMT, high expression on 
UTC and other mechanistic studies (§3.5.1) suggest that PC expression may be upregulated 
as part of an EMT program. If this is so, similar to its function in EMT-independent 
tumours, PC may help to promote a non-cohesive, invasive phenotype during EMT. 
3.5 Small-cell lung carcinoma 
Small-cell lung carcinomas (SCLC) (16% of lung cancers) are malignancies that typically 
arise from epithelial cells of the proximal airways (bronchus). SCLC tumours consist of 
multipotent epithelial (“stem-like”) cells that form typically diffuse and non-cohesive 
clusters. Analysis of formalin-fixed, paraffin-embedded bronchial-tumour biopsies (and 
adjacent normal bronchial tissues) reveals that the majority of SCLC but not normal 
bronchial epithelia expresses PC and its expression in SCLC correlates with non-methlyated 
CpG islands in the PODXL gene (Koch et al., 2008).  
Although PC is not detected in normal adult bronchial epithelium, clusters of PC-positive 
epithelial cells can be detected in deep pockets of developing proximal bronchi and trachea 
of fetal lung (Koch et al., 2008). The authors suggest the intriguing hypothesis that PODXL 
marks multipotent bronchial epithelial cells during lung development and that SCLC 
“cancer stem cells” may retain or acquire the characteristics of this stem-like population. 
There are currently no studies that correlate PC expression with patient outcome or 
response to chemotherapy in lung cancers.  PC expression in non-small cell lung carcinomas 
(NSCLC) was not performed in this study so it is not yet known if PC also marks primary 
NSCLC tumours of the lung. For these reasons, the diagnostic value of PC expression in 
lung cancer is less certain than in other cancers. However, although many technical 
challenges remain, identification of tumour-specific glycoforms of PC (see following 
sections) may provide targets for adjuvant therapy in lung cancer. This is particularly 
important in SCLC where surgical resection of tumours is more difficult. Alternatively, if PC 
expression is consistently associated with type 3 EMT processes in lung cancer (see below), 
or other EMT-dependent cancer metastases, expression of PC (assessed by biopsy or in vivo 
imaging) may herald a switch from locally invasive to a more advanced disease stage. 
3.5.1 Podocalyxin in TGF-mediated epithelial-to-mesenchymal transition (EMT) 
Epithelial-mesenchymal transition (EMT) (type 3) is a paradigm of tumour invasion and 
metastasis whereby epithelial cells lose their apical and basal polarization and robust cell-
cell contacts to become mesenchymal in morphology and adopt an invasive, migratory 
behaviour (Kalluri and Weinberg, 2009). Among many other alterations in gene expression 
patterns, EMT is associated with loss of the adherens-junction regulator E-cadherin (CDH1), 
stabilization and nuclear-localization of -catenin (CTNNB1), and upregulation of the 
intermediate filament protein vimentin (VIM), a mesenchymal marker (Zeisberg and 
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Neilson, 2009). As we have noted above, PC does not appear to be capable of initiating EMT 
on its own. However, Wilkins et al. have recently demonstrated that it may contribute to the 
EMT that is initiated by transforming growth factor beta (TGF (Meng et al., 2011). 
Although TGF has tumour suppressing activity in some cancers, especially at the early stages 
of tumour progression, TGF, in the context of enhanced phosphatidylinositol-3-kinase 
(PI3K)/Akt and other survival signalling pathways can drive EMT processes (Ouyang et al., 
2010). TGF-induced de-differentiation is not limited to malignant cells, as normal human and 
mouse podocytes undergo an EMT-like transition in response to TGF (Herman-Edelstein et 
al., 2011; Li et al., 2008; Wang et al., 2011). A549, a human lung adenocarcinoma cell line, 
undergoes EMT-like transformation in the presence of TGF, with prototypical EMT features 
including down regulation of E-cadherin, upregulation of vimentin, expression of MMP2 and 
fibronectin and, secretion of collagens (type I, III and IV) (Kasai et al., 2005). These alterations 
in gene expression pattern are accompanied with altered cell morphology, loss of cell-cell 
contact and enhanced migration (Kasai et al., 2005; Meng et al., 2011).  
 
 
Fig. 3. PODXL expression is upregulated during TGF-induced EMT of a lung adeno-
carcinoma cell line (A549). Expression profiles where generated by meta-analysis of 
publically available gene expression data using the Gene Expression Omnibus (GEO) 
dataset GDS3710 (Sartor et al., 2010).  
Meng et al recently demonstrated that PC protein expression is upregulated in response to 
TGF(Meng et al., 2011) A query of a publically available gene expression dataset of A549 
cells undergoing TGF-induced EMT corroborates their findings and shows that the 
kinetics of PODXL transcript expression are similar to EMT-associated down regulation of 
E-cadherin (CDH1) transcript (Sartor et al., 2010) (Fig. 3). Intriguingly, using a gene-
silencing approach (shRNA), Meng et al show that PC is required for at least some EMT-
related processes including mesenchyme-like morphogenesis, cell migration and changes in 
expression of E-cadherin and vimentin (Meng et al., 2011). PC was also found to co-
distribute with newly secreted collagen I at the leading edge of migrating TGF-treated 
A549 cells. In addition, collagen I could be co-precipitated with anti-PC antibodies in TGF-
treated A549 cells. Notably, the collagen I-binding integrins (11 and 21) were not 
identified in collagen I-PC complexes or detected in PC-collagen membrane domains. Thus, 
one possible role for PC in a collagen-complex could be the exclusion of collagen- or matrix-
binding integrins from the leading edge of migrating cells and intercellular destabilization 
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of strong adhesion to ECM - themes consistent with our findings using breast and ovarian 
cancer cell lines (§3.2.3 & 3.3).  
We note that in this example, PC expression is down-stream (or parallel) to TGF-induced 
EMT. Thus, while high expression of PC in some tumour cells (e.g, breast carcinoma) can 
promote EMT-independent tumour progression, PC may also support the invasive and 
migratory functions of tumour cells that have undergone EMT. 
3.6 Prostate carcinoma 
A 1.1 Mb region of human chromosome 7q32-33 flanked by microsatellite markers D7S2452 
and D7S684 strongly linked to prostate tumour aggressiveness contains the PODXL locus 
(Neville et al., 2002). In a sibling-pair study, a variable in-frame, germ-line deletion of one or 
two Ser-Pro repeats in the PC mucin domain (deletion of residues 23-24 or 23-26) was found to 
be associated with enhanced risk of developing prostate cancer (increased overall risk (OR)=2-
2.5 fold) and increased tumour aggressiveness (OR=3-4.4 fold) (Casey et al., 2006). In addition, 
a missense single-nucleotide polymorphism (SNP, G340A) resulting in a Ser substitution at 
Gly114 (also in the mucin domain) was associated with a 50% increased risk of prostate cancer 
(Casey et al., 2006). Other SNPs in PODXL were detected but had lesser correlative significance 
to prostate cancer risk or tumour behaviour. We note that, unlike the other cancers discussed 
in this review, this is the only example of a germ-line mutation in PODXL associated with 
increased cancer risk. Although 7q32-33 is a region of high allelic imbalance in prostate cancer, 
this patient study did not specifically address PC protein or transcript expression levels in 
prostate tumours. Although we may not expect that deletion of one or two glycosylation sites 
arising from PODXL polymorphisms would significantly alter PC function, it is possible that 
such in-frame deletions may alter PC surface stability, apical localization or expression and 
therefore account for enhanced aggressiveness of prostate tumours. Alternatively, in-frame 
deletions of mucin domain Ser-Pro may indeed alter the functions of PC’s extracellular domain 
or its association with unknown ligands. Regardless of the associated molecular mechanism, 
PODXL deletion polymorphisms and the G340A missense SNP may provide an additional 
genetic screening method to evaluate prostate cancer risk.  
3.6.1 Forced expression of podocalyxin enhances the motility of prostate cancer cells  
PC3 cells are a human prostatic adenocarcinoma cell line derived from bone metastases 
(Kaighn et al., 1979). PC3 cells, which are considered to have a relatively high metastatic 
potential and invasive phenotype in comparison to other prostate cancer lines, do not express 
detectable levels of PC by western analysis (Sizemore et al., 2007). However, as for other 
epithelial tumour cell lines, forced expression of full-length PC in this prostate cell line 
enhanced cell motility in vitro (Sizemore et al., 2007). This enhanced motility may depend on 
the activation of Rac1 that, in turn, requires the association with two intracellular binding 
proteins, NHERF1 and ezrin. Thus, as for other carcinomas discussed in this review, 
expression of PC in prostate epithelial has the potential to impart a more aggressive phenotype 
with potential clinical importance. Further study of PC expression profiles in primary or 
secondary prostate tumors, coupled to tumour phenotype and outcome data, are required to 
evaluate whether expression of PC has diagnostic value in prostate cancer.  Query of 
microarray gene expression data from normal prostate tissue and primary and secondary 
prostate cancer suggest that PODXL expression may not be altered in primary prostate tumors 
(Fig. 4). Conversely, metastatic tumours originating from the prostate may have increased 
PODXL expression (~1.4 fold) (Fig. 4). Therefore, it is unclear if the increased risk and tumour 
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aggressiveness associated with this PODXL polymorphism is related to altered PC function, 
expression or simply another marker that is linked to allelic imbalance of 7q32-33. 
 
 
Fig 4. Expression of PODXL in normal human prostate tissue and prostate cancer (GEO 
dataset GSE6919) (Chandran et al., 2007; Yu et al., 2004).  The metastatic tumour group is 
significantly different than the normal adjacent and primary tumour groups but not the 
normal donor group (*p < 0.05, Tukey one-way ANOVA analysis). All other group 
comparisons are not significantly different. 
3.7 Testicular cancer and embryonal carcinoma 
Testicular cancer, the most common cancer in young males, has a high cure rate even after 
systemic spread (reviewed in Winter & Albers, 2011). However, risk stratification and 
classification of the primary tumour by histological methods and determination of tumour 
marker levels is important for designing surveillance and systemic treatment strategy in the 
event of metastasis or re-lapses. The vast majority of testicular tumours (95%) can be broadly 
classified as either seminomatous- (SGCT) or non-seminomatous- (NSGCT) germ cell tumours. 
Seminomas are non-pluripotent, undifferentiated germ cell progenitors whereas non-
seminomas tumours are comprised of several subtypes arising from embryonic or 
extraembryonic (e.g., yolk sac) lineages. Embryonal carcinomas and teratomas are examples of 
sub-types of NSGCT. Importantly, treatment strategies for SGCT and NSGCT cancers are 
different, with the major difference being that NSGCTs are generally resistant to radiotherapy. 
PC is antigenically identical to tumour markers originally designated GCTM-2 (or gp200), 
TRA-1-60 and TRA-1-80 expressed on embryonal carcinoma (EC) cell lines and inner 
blastocyst-derived human embryonic stem cells (hESCs) (Schopperle et al., 2003; Schopperle 
& DeWolf, 2007). The TRA-1-60/81 epitopes are present only on a high molecular weight 
form of PC (200 kD) expressed by undifferentiated embryonal carcinoma or hESCs. 
Intriguingly, the antigenic sites detected by these antibodies disappear following retinoic 
acid (RA)-induced differentiation of ECs or following differentiation of ESCs into embryoid 
bodies (EBs) (Schopperle and DeWolf, 2007). However, EBs continue to express a lower 
molecular weight isoform (170 kD) of PC that can be detected using antibodies recognizing 
peptide epitopes, or by the terminal glycan, -(D)-galactose (Gal)-binding plant lectin, 
peanut agglutinin (PNA) (Schopperle and DeWolf, 2007). Thus, there is evidence to suggest 
that there are tumor and tissue type specific epitopes on PC. These epitopes are present on 
primitive or pluripotent germ-line tumours or hESCs. 
GCTM-2 has been identified as a tumour marker of NSGCT and a soluble form of GCTM-2 
has been detected in the sera in 7 of 20 patients diagnosed with NSGCT. In addition, TRA-1-
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60 was present in the sera of over 75% of patients (n=42) with NSGCT and even in two-
thirds of NSGCT patients negative for the “gold-standard” testicular cancer serum tumour 
markers, -fetoprotein and chorionic gonadotrophin (Mason et al., 1991; Badcock et al., 
1999; Gels et al., 1997 as cited in Schopperle et al, 2003). Although the mechanism has not yet 
been defined, serum-soluble forms of PC may arise from secreted isoforms or proteolytic 
cleavage (membrane shedding) of the membrane anchored protein. These findings suggest 
that PC; especially a modified, high molecular weight form preferentially expressed in 
undifferentiated embryonic lineages, may serve as a sensitive tumour marker detectable in 
patient serum. Thus, with further validation, the detection of soluble PC peptide fragments 
could aid in detection of testicular germ-line tumours and evaluating response to therapy. 
3.7.1 Epigenetic regulation of podocalyxin by micro RNA in testicular cancer 
In a screen of gene methylation patterns in the a human testicular tumour cell line (NT2) (an 
embryonic carcinoma), Cheung et al (Cheung et al., 2011) recently identified a 
hypermethylated region in intron 14 of the dynamin 3 locus (DNM3) located on chromosome 
1(q24). This region codes for the expression of three micro RNAs (miR), including miR-199a2 
(hsa-mir-199a-2) in an antisense orientation. miR-199a2, together with miR-199a-1 (located on 
hChr 19p13), encode the pre-microRNA species miR-199a. Reduced expression of miR-199a 
has previously been linked to poor prognosis in serous ovarian carcinoma (Nam et al., 2008) 
and pro-inflammatory and anti-apoptotic pathways in chemoresistant ovarian cancer stem 
cells (Yin et al., 2010). miR-199a, which is normally abundantly expressed in most human 
epithelial and non-epithelial tissues (with the notable exception of brain and peripheral blood 
mononuclear cells (Liang et al., 2007)), targets a cluster of genes that include transcripts 
encoding PC, HIF-1, IKK and SIRT1, mTOR, SMAD1 and c-MET and several others 
(Cheung et al., 2011). Note that regulation of these targets by miR-199a and expression of the 
miR-199a-1 and miR-199a-2 loci is tissue specific. For example, reduced expression of miR-
199a (along with other miRs) has also been linked to bladder cancer (Ichimi et al., 2009). 
Conversely, miR-199a expression is upregulated with a cluster of other miRs in metastatic 
uveal melanoma and gastric cancer (Ueda et al., 2010; Worley et al., 2008). 
The miR-199a2 pre-microRNA is processed to yield two mature miR species, miR-199a-5p 
and miR-199a-3p, and both are down regulated in malignant testicular tumours in 
comparison to normal or benign tumour tissue (Cheung et al., 2011). miR-199a-5p and -3p 
have distinct RNA targets, and only miR-199a-5p is a direct negative regulator of PODXL. 
Expression of miR-199a-5p negatively correlates with PC protein expression in malignant 
testicular tumors (both seminomatous and non-seminomatous) (Cheung et al., 2011). Ectopic 
expression of miR199-a in NT2 cells attenuates migration and invasion in vitro and tumour 
growth and metastatic potential in xenograft transplant models. Suppression of PODXL in 
NT2 cells by RNAi also attenuates matrix invasion in an in vitro assay. These data suggest 
that epigenetic regulation of the ha-miR-199a-2 locus by CpG methylation results in 
repression of miR-199a2 expression and upregulation of PODXL and that these events 
correlate with tumour malignancy in testicular cancer. Other targets of miR-199a-5p and -3p 
are also likely involved in the invasive phenotype of testicular tumours. 
3.8 Gastrointestinal cancers 
3.8.1 Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is a common adult liver malignancy associated with 
infection by hepatitis (HVB and HVC) and cirrhotic liver disease. Patients with cirrhosis 
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from a variety of causes are at an increased risk of developing HCC. Unfortunately, the 
majority of HCC patients (>80%) present with systemic or locally advanced tumours that 
cannot be cured surgically. Although recently, the application of anti-angiogenic drugs (e.g., 
sorafenib) has shown promise in slowing tumour growth in HCC patients, chemotherapy 
and radiotherapy are ineffective, and HCC has a very low five-year survival rate (~5%). 
Prompt detection and diagnosis of HCC in cirrhotic liver by imaging methods or 
histological assessment of biopsy is critical for designing an effective treatment strategy.  
Although one group showed that PC was only weakly present in 9% of HCC tumours (i.e., 
neoplastic liver epithelial cells) (Ney et al., 2007), PC and CD34 were commonly upregulated 
on sinusoidal endothelia associated with primary HCC tumour tissue (Chen et al., 2004; 
Heukamp et al., 2006). In contrast, in normal liver tissue, PC is restricted to hepatic arterioles 
(Heukamp et al., 2006). PC and CD34 are also present (in a more punctuate pattern) on the 
sinusoidal endothelia of hyperplastic focal nodules and liver adenomas (Heukamp et al., 
2006). Thus, expression of PC (and CD34) may provide an additional diagnostic marker for 
the evaluation of liver biopsies in HCC. PC and CD34 are widely expressed in vascular 
endothelia in adult tissues but their function remains ill-defined. Although PC has been 
shown to play a role in the formation of vascular lumens in the developing embryo, it is not 
essential for the homeostatic maintenance of vascular endothelia in adults (at least in mice). 
Nevertheless, mounting evidence suggests that PC and CD34 have a role in the formation of 
new vessels during development and vascularization of solid tumours; and, the 
maintenance of vessel integrity in inflamed tissues (Blanchet et al., 2008; Maltby et al., 2011; 
Strilic et al., 2009). Thus, further study of the role of CD34 and PC in neovascularization and 
vessel homeostasis may provide new targets for anti-angiogenic treatments for solid 
tumours. 
3.8.2 Pancreatic ductal adenocarcinoma 
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic cancer, often 
detected at an advanced stage. Because there are no effective systemic therapies, PDAC 
diagnosis typically has a very poor prognosis (~3% 5-yr survival). Determining the primary 
source of adenocarcinoma is important in treatment strategies and prognosis. Neoplasms 
originating from the pancreatic duct, gall bladder, bile duct, ampulla of Vater and 
duodenum are difficult to distinguish by immunohistology alone since many express a 
similar profile of epithelial cytokeratin- and mucin-family proteins. Immunohistochemical 
analysis of primary adenocarcinoma and carcinoma tumours of gastrointestinal, pancreatic 
and extrapancreatic origin suggest expression of PC is associated with primary epithelial 
neoplasms of the pancreatic duct (44%) or ampullary origin (30%) (Ney et al., 2007). 
Although PC is expressed is less than half of these adenocarcinomas, it is not detected (or 
very weak) in normal or inflamed pancreas (chronic pancreatitis) or in most primary 
tumours from all other gastrointestinal sites including bile duct. Although these data 
suggest that expression of PC may be useful for the differential identification of primary 
adenocarcinoma, it is not known if PC expression at secondary tumour sites correlates with 
their primary origin. However, expression of PC does appear to correlate with more 
advanced histological tumour grade, as 53% of Grade 3, 48% of Grade 2 and 18% of Grade 1 
tumours express PC (Ney et al., 2007). Thus, as with several other epithelial malignancies 
described in this review, expression of PC correlates with a more anaplastic, poorly 
differentiated phenotype and more aggressive (or advanced) cancers. 
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3.8.3 Colorectal cancer 
Although the expression of PC has not been verified in primary or metastatic tumours in 
human colorectal cancer, two studies have identified PC expression in colon cancer cell 
lines, and PC protein as a shed, soluble component of colon cancer cell cultures (Ito et al., 
2007; Thomas et al., 2009) In addition, Thomas et al (Thomas et al., 2009) demonstrated that 
PC, immunopurified from a colon cancer cell line (LS174T), can act as an E- and L-selectin 
ligand (but not P-selectin) using a PC-coated microbead flow adhesion assay.  E/L-selectin 
binding was dependent on a sialofucosylated epitope of PC expressed in LS174T, similar to, 
but distinct from sulfated sLex epitopes present on sialomucins processed in HEV (see §5.2) 
(Thomas et al., 2009). Thus, tumor-specific modifications (glycosylation) of PC may allow for 
interaction with selectins. 
Importantly, neither of these studies showed that PC protein is expressed on the surface of 
colon carcinoma cells (as opposed to intracellular), or that PC serves as an E/L-selectin 
adhesive ligand in vitro or in vivo.  If PC were indeed shown to be a bona fide E/L-selectin 
ligand on these carcinomas, this would offer an attractive target for the development of 
adjuvant therapies. This is especially true if the unique modification of PC detected in human 
colon cancer cell lines is recapitulated in primary and metastatic colorectal adenomas and 
carcinomas. Retrospective analyses of tissue microarrays of primary colorectal carcinomas and 
adenocarcinomas (and perhaps metastatic, secondary tumour sites) similar to those performed 
for RCC and breast cancer are required to determine if expression of PC is associated with 
colorectal cancers and if expression correlates with patient outcome. At least one study (Ney et 
al., 2007) suggested that PC is not commonly expressed in gastrointestinal tumours, including 
colon-derived, with the exception of pancreatic cancers.  Then again, this is also true for breast 
and renal cancer – the prognostic power of evaluating PC expression in human cancer appears 
to be in identifying rare, highly lethal sub-types. 
3.9 AML, ALL and cutaneous myeloid sarcoma 
PC expression has been reported on a human monocytic cell line (U937) after induced 
differentiation with vitamin D3 and transforming growth-factor beta (TGF) and on normal 
human monocytes treated with macrophage colony-stimulating factor (MCSF) for 3-6 days 
in vitro (Riccioni et al., 2006). In both cases, PC expression correlates with a more 
differentiated, monocytic cell-surface marker phenotype (e.g., CD14+CD11b+). However, PC 
expression has not been reported on human monocytes derived from normal bone morrow 
(BM) or peripheral blood (Kelley et al., 2005). 
Kelley et al (Kelley et al., 2005) found that PC is often expressed on leukemic blasts 
including 77% (n = 39) of acute myeloid leukemia (AML), 81% (n = 27) acute lymphoid 
leukemia (ALL) and 87% (n=15) cases of cutaneous myeloid sarcoma (Kelley et al., 2005). 
Expression of PC was detected in all clinical sub-types of AML (M1-M7) and both T and B-
cell lineage ALL. A second study reported a much lower frequency of PC-positive blasts in 
73 cases of AML with approximately 20% of cases presenting with a moderate frequency of 
PC-positive cells (20-50% positive blasts (+)) and 18% displaying high frequency (>50% 
positive blasts (++)) (Riccioni et al., 2006). Importantly, while Kelley et al used 
immunohistochemical analysis of formalin-fixed BM biopsy tissue and PC was observed in 
a punctuate, cytoplasmic distribution; Ricconini et al used freshly isolated BM or peripheral 
blood-derived leukemic blasts and flow cytometery analysis (i.e., cell-surface expression of 
PC). Thus, while PC is commonly expressed in leukemic blasts in the BM, cell-surface 
exposure of PC is likely more rare (at least in AML). 
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There are no studies that address the clinical consequences of PC expression in leukemia. 
Expression of PC in hematopoietic malignancies may reflect transformation of an immature 
progenitor that normally expresses PC or a “de-differentiation” gene expression pattern of a 
leukemic stem cell. We have found that expression of PC in mouse hematopoietic stem or 
progenitor cells (HSC/Ps) enhances CXCR4-induced chemotaxis and BM-homing/retention 
(see §6.2.3) (Nielsen & McNagny, 2009a) (and our unpublished observations). Thus, one 
possible consequence of PC overexpression in leukemia may be that PC enhances close 
contact to CXCL12-secreting cells and, subsequently, an advantage (over normal 
hematopoietic progenitors or PC-negative leukemia) with to respect retention, proliferation, 
survival or chemo-resistance of leukemic cells. 
3.10 Malignant astrocytic tumours 
Astrocytomas, tumours originating from astrocytes of the brain and spinal cord, are the 
most common neoplasm of the central nervous system (Zhu & Parada, 2002). Often 
presenting at an advanced stage, astrocytic tumours are classified into four histological 
grades that broadly include benign (I), diffuse (low-grade) (II), anaplastic astrocytoma (III) 
and glioblastoma (IV). The most aggressive, glioblastoma (GBM), is also the most common 
malignant astrocytic tumour with a 5-year survival rate of less than 3%. Although 
systematic metastasis of astrocytomas is rare, aggressive local invasion into surrounding 
tissue, rapid growth and resistance to apoptosis accounts for the lethality of these brain 
cancers – tumour behaviours supported by aggressive angiogenesis (Anderson et al., 2008). 
In a study of 51 astrocytomas using immunohistochemical staining of frozen sections, 
immunoblotting of tumour lysates and quantitative real-time PCR, PC expression was 
found to be present in approximately half of the cases of anaplastic astrocytoma and GBM, 
but none of the lower-grade astrocytomas (Hayatsu et al., 2008). The pattern of staining in 
the anaplastic astrocytomas is consistent with cell-surface expression of PC; however, PC 
localization in GBM was more diffuse and PC-positive tumour cells were associated with 
regions of microvascular proliferation. Using a lectin-binding microarray combined with a 
mass spectrometry approach, another group detected PNA-reactive PC abundantly 
expressed on the surface of a “stem cell like” human GBM cell line (GBM1), but not on an 
adherent GMB line (U373) (He et al., 2010). 
Notably, the sialomucin podoplanin (PDPN), which shares some striking structural and 
functional properties with PC, is also highly expressed in glioblastoma (Mishima et al., 
2006). Podoplanin is expressed on the outer/invasive edge of some tumours and is thought 
to have a role in the anti-adhesive phenotype of EMT-independent tumour invasion (Wicki 
and Christofori, 2007). Invoking a similar paradigm to breast and ovarian carcinoma (§3.2.3 
& 3.3), we posit that high expression of PC may promote an EMT-independent 
morphogenesis that, combined with other transforming pathways, promotes an invasive 
phenotype in astrocytomas. 
4. Podocalyxin marks embryonal carcinomas and embryonic stem cells 
PODXL transcript and protein is down regulated in embryoid bodies (EB) and lineage-
restricted EB cultures compared to undifferentiated human embryonic stem cells (hESCs) 
(Brandenberger et al., 2004; Cai et al., 2006). PC-binding antibodies TRA-1-60 and TRA-1-81, 
together with membrane surface, stage-specific embryonic antigens (SSEA)-3 and SSEA-4; 
and, intracellular markers alkaline phosphatase, telomerase, Oct4 and Nanog are routinely 
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used to characterize undifferentiated hESC (De Miguel et al., 2010; Palecek, 2011). As 
mentioned previously, the TRA-1-60 and TRA-1-81 epitopes are present only on the high 
molecular weight form of PC detected in embryonal carcinoma (EC) cell lines and these 
markers are lost upon induced differentiation of EC or hESC. Thus, PC is a marker of 
undifferentiated human embryonal cells and PC is either alternately modified (e.g., 
glycosylation pattern) or its expression is reduced upon differentiation. In an effort to 
identify novel markers of undifferentiated hESC, Choo et al generated an anti-PC antibody 
(IgM isotype, mAb 84) cytotoxic to undifferentiated hESC (human embryonic stem (HES) 
cell lines HES-2, -3 and -4) and at least one embryonal carcinoma cell line (NCCIT) (Choo et 
al., 2008). Importantly, mAb 84 is not cytotoxic to mature human cell lines (HEK-293, HeLa) 
or hESC induced to differentiate by withdrawal of fibroblast growth factor 2 or following 
culture of hESC to form EB (day 22). Remarkably, mAb 84 rapidly (< 45 minutes) kills EC 
even at 4°C. The mechanism for mAb 84 cytotoxicity is not dependent on complement 
activation, hypercrosslinking of bound antibody or antibody internalization. Instead, mAb 
84 mediates cell death by oncosis initiated by PC-mediated reassembly of cytoskeleton, 
degradation of cytoskeletal structural proteins (-actinin, talin and paxillin), PC-aggregation 
and formation of large membrane pores (Tan et al., 2009). Since crosslinking other PC-
specific antibodies bound to hESCs is not cytotoxic, the association of mAb 84 to a unique 
PC epitope (or potentially other additional unknown epitopes on hESCs) induces 
cytoskeletal reassembly in advance of PC aggregation and pore formation. Studies with 
antibody fragments revealed that cytotoxicity requires divalency with sufficient flexibility 
linking the antigen binding domains (Lim et al., 2011). Since pre-treatment of HES-3 hESC 
and NCCIT cultures with mAb 84 in vitro prevents teratoma formation in a severe combined 
immunodeficient (SCID) mouse xenograft model mAb 84 has potential applications in 
clearing tumour-forming undifferentiated hESCs from cultures of differentiated hESCs 
intended for cell-based, regenerative therapies (Choo et al., 2008; Tan et al., 2009). With 
respect to the treatment of cancer, a cytotoxic antibody like mAb 84 may also prove to be an 
effective oncolytic adjuvant therapy in germ-line tumours like testicular cancer (especially 
embryonal carcinoma subtype). This approach, of course, would require highly selective 
targeting of tumour-specific forms of PC to avoid renal toxicity. The encouraging example of 
mAb 84 suggests that highly selective targeting of PC expressing tumour cells in vivo may be 
possible. 
5. Podocalyxin structure and function 
In an effort to determine how expression of PC on cancer cells promotes tumour 
aggressiveness and metastasis, several groups, including our own, have performed 
structure-functional analyses in model cancer cell lines to delineate the specific roles of PC’s 
protein domains in the regulation of cell morphology, motility and survival. The following 
sections summarize some of what is known of the molecular mechanisms regulated by PC. 
PC’s highly charged and bulky extracellular domain imparts a biophysical anti-adhesive 
property that regulates cell morphology and cell-cell adhesion functions and, when 
appropriately modified, may also promote adhesion by binding to L- or E-selectin. The 
intracellular domain links apically-polarized PC to the cortical actin cytoskeleton. By 
recruiting ezrin and NHERF-1/2, PC’s intracellular domain localizes signalling complexes at 
apical membrane domains. In general, expression of PC promotes cell motility and invasion 
functions in epithelial cells and promotes chemotaxis in hematopoietic cells. 
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Fig. 5. Podocalyxin associates with NHERF-1/2 and ezrin to nucleate a variety of 
intracellular signalling complexes.  
5.1 Podocalyxin is a CD34-family sialomucin 
Podocalyxin is one of three members of the CD34-family of sialomucins that also includes 
CD34 and endoglycan (reviewed in Furness & McNagny, 2006). Mucins are members of a 
large class of secreted and type I transmembrane proteins that contain at least one 
extracellular domain rich in proline, serine and threonine residues (PTS domain). Mucin 
domains are extensively modified by post-translational addition of O-linked 
oligosaccharides (at S/T residues) and frequently modified by N-linked glycosylation and 
sulfation. Sialomucins, in particular, are also heavily modified by the addition of a 
terminal sialic acid to terminal O-linked glycans. PC is a sialomucin that, together with 
CD34 and endoglycan, makes up the CD34-family (reviewed in Furness and McNagny, 
2006). The mature, cell surface expressed human PC protein is a 536 residue glycoprotein 
with a calculated peptide mass of 56 kilodaltons (kD); however, glycosylation and other 
post-translational modifications yield a product with an apparent molecular weight of 
150-200 kD. The extracellular domain of PC consists of a heavily O-linked glycosylated, 
sialated and sulfated mucin domain, a globular domain containing a conserved four-
cysteine (Cys) motif, and, a membrane-proximal stalk domain. Three or four sites of N-
linked glycosylation also decorate the extracellular domain. Together, these modifications 
result in a highly negatively charged, sterically bulky glycoprotein (Fig. 5). Although the 
primary amino acid sequence of PC’s extracellular domain is not well conserved by 
paralogs (or CD34-family homologs), the intracellular domain is highly conserved across 
species. 
5.2 Extracellular ligands of podocalyxin 
The only well-established extracellular ligand for CD34-family sialomucins is L-selectin 
(reviewed in (Furness & McNagny, 2006; Nielsen & McNagny, 2008)), however there are 
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also reports to suggest that, when appropriately modified, they may also bind E-selectin 
(Thomas et al., 2009). Selectins are a family of mammalian C-type lectin carbohydrate-
binding proteins normally expressed by hematopoietic cells (L- and P-) or endothelia (P- 
and E-) (Laubli & Borsig, 2010). L-selectin is responsible for naïve homing of leukocytes to 
secondary lymphoid organs; whereas, P- and E-selectins play a predominant role in 
mediating homing of white blood cells to inflamed (or specialized) tissues. Recognition of 
CD34-family sialomucins by selectins requires an unusual carbohydrate post-translational 
modification (sulfated sialyl Lewis-X (sLeX)). Although this modification is present on 
CD34-family sialomucins expressed by high endothelial venules (HEV) of lymph nodes, it is 
not typically found on CD34-type proteins expressed by non-lymphoid endothelia (the vast 
majority of all endothelia). Thus, although selectin-binding functions for CD34 sialomucins 
(including PC) have been demonstrated in vitro, the biological significance of this function is 
unclear for most endothelium in vivo. Nevertheless, the interaction of tumour cells with 
selectins (or expression of selectins or selectin ligands by tumour cells) is an important 
paradigm in cancer metastases (reviewed in Laubli & Borsig, 2010). Thus, aberrant 
modification (sLeX) or enhanced expression of PC in malignant cells (Kannagi, 2004) may 
facilitate selectin-mediated tissue homing and trafficking. 
5.3 Intracellular binding partners of podocalyxin 
The intracellular domain of PC contains a membrane proximal ERM (ezrin, radixin, 
moesin)-protein association domain, as well as putative target sites for serine and threonine 
(S/T) kinases (e.g., casein kinases I/II (CKI/II) and protein kinase C (PKC)) and protein 
tyrosine kinases (PTK) (Fig. 5). In addition, the four C-terminal amino acids of the 
intracellular domain, aspartate-threonine-histidine-leucine (DTHL) is an interaction motif 
for proteins containing a PSD-95/Dlg/ZO-1 (PDZ)-domain.  
The best-characterized intracellular binding partners for PC are ezrin and NHERF isoforms 
1 and 2 (solute carrier family 9 (Na+/H+ exchanger), member 3 regulator -1 and -2) (Fig. 5). 
Notably, dysregulated expression, localization and mutants of ezrin and NHERF-1 (also 
called EBP50) and -2 have been implicated in human cancers (Dai et al., 2004; Brambilla & 
Fais, 2009; Mangia et al., 2009; Hayashi et al., 2010). As adaptor proteins with diverse 
binding partners, ezrin and NHERF-1/2 have the potential to link PC to several signalling 
pathways (see Table 2). Likewise, by targeting ezrin and NHERF-1/2 to select apical 
membrane domains, PC may regulate the localization, function and availability of these 
complexes. 
5.3.1 NHERF-1 and NHERF-2 
NHERF-1 and -2 both have two tandem PDZ domains - the centrally located PDZ class II 
domain associates with PC’s C-terminal DTHL motif, leaving NHERF’s N-terminal PDZ 
class I domain free to interact with other binding partners. Table 2 provides a partial list of 
known NHERF-1/2 binding partners. Ezrin can either directly binds to PC via the 
membrane proximal ERM protein-binding motif or indirectly via the C-terminal ERM motif 
of NHERF-1/2. NHERF-1/2 have a wide range of binding partners that include ion 
channels, G protein coupled receptors, receptor tyrosine kinases (RTKs), intracellular 
signalling intermediates and -catenin, a transcription factor (Table 2). NHERF-1/2 may 
also homodimerize or polymerize via PDZ-domain interactions, or bind other PDZ domain 
containing proteins like PDZ K1 (Garbett et al., 2010). 
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NHERF-1/2 binding partners Ezrin binding partners
Sialomucins 
Podocalyxin, endoglycan (but not CD34) 
 
Receptor tyrosine kinases 
Epidermal growth factor receptor (EGFR),  
Platelet derived growth factor receptor (PDGFR) 
 
G protein coupled receptors 
β2-adrenergic receptor, κ-opiod receptor,  
Frizzled isoforms (Wheeler et al., 2011),  
Parathyroid hormone receptor, P2Y1 purinergic receptor 
 
Ion channels 
Cystic fibrosis transmembrane conductance regulator 
(CTFR),  
Na+/H+ exchanger member 3 (NHE3) 
TRPC4 (transient receptor potential cation channel 4)  
(Lee-Kwon et al., 2005) 
Mrp2 (multidrug resistance-associated protein 2) (Li et 
al., 2010) 
 
Transcription factors 
β-catenin 
 
PDZ domain proteins 
PDZ K1 (Garbett et al., 2010),  
NHERF-1/2 (homodimer or polymer) 
 
ERM proteins 
Ezrin, radixin, moesin, merlin  
 
PI3K pathway regulators 
PTEN (Takahashi et al., 2006),  
Akt (Wang et al., 2008)   
 
Rho-family regulators or downstream effectors 
ARHGEF7 (Hsu et al., 2010),  
RACK1 (Liedtke et al., 2004) 
Sialomucins 
Podocalyxin, CD44, CD43, PSGL-1 
 
Non-receptor tyrosine kinases 
Focal adhesion kinase (FAK),  
Src-family kinase (SFKs) 
 
Integrin-binding adhesion molecules 
Intercellular-adhesion molecules  
(ICAMs)  -1, -2 & -4 
 
Serine/threonine kinase 
Protein kinase A (PKA) 
 
Phosphatidylinositol 3-kinases 
p85 of class I PI3Ks 
 
Cytoskeleton/adaptors 
F-actin, NHERF-1/2 
 
Membrane phospholipids 
PI (4,5) P2 
 
Ca2+ signaling effectors 
S100P (Austermann et al., 2008) 
 
Rho-family regulators or downstream 
effectors 
RhoGDI (Schmieder et al., 2004) 
Table 2. A partial list of reported binding partners of NHERF-1/2 and ezrin. Specific binding 
references are shown in the table. For reviews of NHERF-1/2 binding interactions see 
references Weinman et al., 2006; Georgescu et al., 2008; Nielsen and McNagny, 2009 & Hayashi 
et al., 2010. Ezrin binding interactions were recently reviewed in Bambilla & Fais, 2009.  
5.3.2 Ezrin 
Ezrin acts as an intracellular adaptor to provide linkage of integral membrane proteins with 
the cytoskeleton. Ezrin contains an N-terminal FERM protein-interaction domain capable of 
binding the intracellular domain of several type I transmembrane proteins, NHERF-1/2, 
RhoGDI and the membrane lipid, phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2), and a 
C-terminal domain that bind polymerized actin (F-actin) (Table 2). The C-terminal domain 
of ERM folds over to associate with its N-terminus in an inactive conformation and  
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phosphorylation of a conserved Thr residue in the C-terminus, downstream of Rho kinase, 
protein kinase C isoforms (and other S/T kinases), induces an open conformation that 
permits ERM proteins to link complexes to polymerized actin (F-actin) (Fehon et al., 2010). 
Phosphorylation of Tyr residues (perhaps by RTKs or Src-family kinases) further enhances 
ezrin activation or activation of ezrin-dependent signalling events. By using NHERFs as an 
adaptor, ezrin can link several other transmembrane proteins to the cytoskeleton including 
ion channels and GPCRs. We note that PC is one of few transmembrane proteins that can 
bind ezrin both directly and indirectly through NHERF-1/2.  
6. The molecular basis for podocalyxin function in tumour metastasis  
At least some of PC’s molecular functions in normal and neoplastic tissues can be explained 
by viewing PC as a key electrostatic anti-adhesive force between extracellular membrane 
surfaces (Gelberg et al., 1996; Takeda et al., 2000; Galeano et al., 2007; Strilic et al., 2009). 
However, since the intracellular domain of PC is phosphorylated on Ser/Thr and Tyr 
residues and PC assembles signalling complexes in response to cell activation, PC 
undoubtedly influences the behaviour of tumour cells by regulating intracellular signalling 
pathways. Some of these intracellular signalling complexes likely reinforce the localization 
of PC to the apical membrane of polarized cells. However, they may also enhance (or 
otherwise regulate) downstream signalling events important in the rearrangement of 
cytoskeleton and adhesion-independent survival. We propose the extracellular domain of 
PC is necessary and sufficient for PC’s homotypic anti-adhesive functions and 
morphogenesis of apical membranes. However, stable apical localization of PC, and its 
effects on the migration and, potentially, survival-promoting functions depends on the 
intracellular domain and assembled signalling complexes. In the next section we will review 
the proposed molecular signalling mechanisms regulated by PC and relate these signalling 
functions to PC’s role as a promoter of tumour progression and metastases. 
6.1 Podocalyxin regulates adhesion and membrane morphogenesis in epithelial cells 
Many of the molecular functions of PC, including signalling mechanisms mediated via ezrin 
and NHERF-1/2, have been elucidated using the human breast cancer cell line MCF7, the 
human prostate cancer line PC3 and the canine renal tubule cell line, Madin-Darby canine 
kidney (MDCK). Since human RCC arise from renal tubule cells, the MDCK model cell line 
may offer valuable insights into the molecular mechanisms of tumour progression and 
metastasis in RCC. Although renal tubules in human and rabbit do not express detectable 
levels of PC protein, MDCK cells and adult canine kidney tubular cells have detectable PC 
(Cheng et al., 2005; Meder et al., 2005). As mentioned in previous sections, MCF7 and PC3 
cells are derived from metastatic breast and prostate tumours, respectively. Both of these 
cell lines express low to moderate levels of PC and are therefore useful for in vitro and in 
vivo assays using methods to force expression of PC or structural mutants of PC. 
Conversely, RNAi methods can be used to study the functions of endogenous PC in tumour 
cells or cell lines. Although there are discrepancies in the assignment of functional roles to 
PC’s structural domains (see details below), taken together, these studies show that high 
expression of PC results in enhanced motility, invasiveness and destabilization of epithelial 
cell morphology in 2D- and 3D-cultures. These phenotypes are characteristics of aggressive 
epithelial tumours with propensity to metastasize. 
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6.1.1 Podocalyxin’s function in epithelial architecture and morphogenesis 
Although MCF7 cells express moderate levels of PODXL transcript (Kao et al., 2009) (Fig. 1); 
by western blotting and immunofluorescence confocal microscopy, expression of PC is low or 
not detected, respectively (Nielsen et al., 2007; Sizemore et al., 2007; Somasiri et al., 2004). In 
order to study the molecular function of PC in breast epithelial cells, others and we have 
ectopically expressed full-length PC and a series of structural mutants in MCF7 (Fig. 6). 
Overexpression of full-length PC (FL) in MCF7 results in apical bulging of monolayers, 
reduced transepithelial resistance (i.e., disrupted cell junctions), delamination and shedding of 
cells from monolayers in vitro (Nielsen et al., 2007; Somasiri et al., 2004). Strikingly, expression 
of PC in MCF7 (and MDCK) potently induces formation of apical microvilli. Epithelial 
microvilli are common features in specialized epithelial layers involved in the secretion or 
absorption of nutrients, vesicles and proteins from the extracellular space (Lange, 2011).  
 
 
Fig. 6.  Schematic of podocalyxin protein structural mutants used to delineate biological 
functions of specific protein domains. EC- extracellular (O-glycosylated mucin) domain, G – 
globular domain, S- stalk domain, TM- transmembrane domain, CT –cytoplasmic domain.  
Triangle in membrane proximal CT domain denotes ezrin-binding motif. Adapted from 
Meder et al, 2005 & Nielsen et al, 2007. 
As we anticipated, full-length, exogenously expressed PC recruits NHERF-1, ezrin and F-
actin to apical membrane domains and forms microvilli in MCF7 cells. However, 
surprisingly, the intracellular domain of PC is dispensable for the formation of microvilli 
since the transmembrane-anchored extracellular domain alone (CT) is sufficient to drive 
morphogenesis and the recruitment of ezrin and F-actin to apical membranes and microvilli 
in MCF7 (Nielsen et al., 2007). Notably, NHERF-1 is not recruited to apical domains or 
microvilli in the absence of PC’s C-terminal DTHL domain (DTHL or CT). This result 
suggests that the extracellular domain, likely by a biophysical charge- and steric-based 
intermolecular repulsion mechanism, can drive membrane morphogenesis and  
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rearrangement of the cytoskeleton (including nucleation of ezrin and F-actin in microvilli) to 
support stable microvilli. We note that this biophysical mechanism requires high expression 
of PC since endogenous levels of PC in MDCK and MCF7 are not sufficient to drive 
microvillus formation. However, such high expression of PC may have relevance in some 
human epithelial cancers, including the rare sub-sets of high PC-positive metastatic breast 
cancer and renal cell carcinomas mentioned previously. 
Although many investigators agree that PC, NHERF-1/2 and ezrin form a complex that 
marks apical membrane domains, the mechanism of PC’s apical targeting is not yet certain. 
We have found that expression of full-length PC (FL), and PC mutants CT, DTHL and 
EC (Fig. 6) in MCF7 result in sorting of these exogenously expressed proteins to the apical 
membrane domain. Conversely, using a similar series of PC mutants expressed in MDCK 
cells, two other laboratories show that precise apical targeting of PC requires its intracellular 
domain (Cheng et al., 2005; Meder et al., 2005). In these studies, although the majority of 
intracellular-deletion PC mutants were still sorted to the apical domain, only full-length PC 
with an intact O-linked glycosylation extracellular domain plus an intracellular domain was 
targeted to apical domains in a way that precisely co-localized with endogenous PC. A GPI-
linked PC extracellular domain mutant (GPI-EC, Fig. 6) displayed the most non-restricted 
membrane localization, suggesting that the transmembrane region of PC may play a role in 
excluding PC from basal lateral membranes and cell-cell contacts. However, Meder et al 
show that a non-membrane anchored construct of PC is predominantly secreted from the 
apical face, thus suggesting that the extracellular domain dictates initial apical sorting of PC 
in epithelial cells (Meder et al., 2005). Thus, although the extracellular domain of PC may be 
sufficient for initial apical distribution, the ezrin and NHERF-1/2 binding determinants in 
the intracellular domain reinforce and stabilize the apical targeting of PC in polarized 
epithelial sheets.  
The above studies were performed by expressing PC constructs in epithelial cell lines that 
express low to moderate levels of endogenous PC.  Using a siRNA-mediated gene-silencing 
approach to knockdown PODXL in MDCK cells, Meder et al show that endogenous PC is 
required for appropriate polarization of epithelial sheets and lumen formation in MDCK 
clusters in a 3D semi-solid culture medium containing extracellular matrix components 
(Meder et al., 2005). While the parental MDCK line formed organized spheres with a 
central lumen when suspended in matrix, deletion of PC disrupts this architecture, and 
MDCK fail to form an organized lumen (Meder et al., 2005). Correspondingly, using 
siRNA-mediated knockdown of endogenous PC in MDCK, Cheng et al show that 
endogenous PC is required for hepatocyte growth factor (HGF)-induced tubulogenesis 
(Chen et al., 2005). Transfection with siRNA-resistant PC (FL) and mutant constructs 
reveals that tubule formation of MDCK requires the intracellular domain. However, PC’s 
extracellular O-linked glycosylated mucin domain has a role in refining the architecture of 
tubule lumens. Finally, enforced expression of PC in MDCK cells inhibits cell-cell adhesion 
and disrupts junctional complexes. This effect is dependent on sialylation of PC, suggesting 
a charge-repulsion mechanism. 
6.1.2 NHERF-herding function of podocalyxin’s intracellular domain 
Although the mechanisms responsible for the apical localization of PC require further 
investigation, it is clear that one of PC’s functional roles is the recruitment of adaptor 
proteins to apical domains. By binding ezrin and NHERF-1/2, PC has the potential to 
impact the activity or compartmentalization of a variety of signalling pathways. While some 
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of PC’s functions can be explained purely by invoking a biophysical charge/steric-repulsion 
paradigm, several biological functions of PC undoubtedly require recruitment of ezrin and 
NHERF into apical-domain signalling complexes.  Since PC can recruit and restrict NHERF 
and ezrin (and potentially their numerous binding partners (Table 2)) to apical membrane 
domains, we posit that many of PC’s functions stem from the concentration of signalling 
complexes – either down regulating signals in other membrane domains (e.g., adherens 
junctions or focal adhesions) or enhancing signals in the apical domains. 
Cortactin (CTTN) is an F-actin- and Arp2/3-binding adaptor involved in the branching and 
nucleation of the cortical actin cytoskeleton and formation of membrane protrusions 
(reviewed in Weaver, 2008). Cortactin’s localization and functional activation is regulated by 
a large number of binding partners. Importantly, cortactin is enriched in cell protrusions 
called “invadopodia” and has a role in the invasion of tumour cells through extracellular 
matrix (Weaver, 2008). PC was found to co-localize with cortactin (and perhaps directly or 
indirectly bind) at the apical domain of rat podocytes (Kobayashi et al., 2009). Effacement of 
podocytes caused phosphorylation of cortactin, dissociation of cortactin from PC/apical 
domains and translocation of cortactin to the basolateral face (Kobayashi et al., 2009). 
Although the interaction of cortactin and PC in invasive tumours has not yet been 
examined, PC localizes to “invadopodia”-like protrusions in in vitro assays. Furthermore, 
cortactin is known to regulate the secretion of MMPs at invadopodia. In this way, and by 
recruitment of NHERFs and ezrin, PC may regulate changes in cortical actin assembly 
associated with tumour invasion and metastasis. This idea is supported by an experiment 
showing that forced expression of PC in MCF7 enhances expression and secretion of matrix 
metalloproteinases (MMP)-1 and MMP-9 (Sizemore et al., 2007).  
6.2 Podocalyxin’s role in the regulation of tumour growth, adherence-independent 
survival and cell motility 
6.2.1 Regulation of Rho-family GTPases 
In MDCK cells, formation of a PC-NHERF-1-ezrin ternary complex regulates RhoA 
activation (Schmieder et al., 2004). As part of a regulatory cycle controlling activation state 
of RhoA, RhoGDI maintains RhoA in an inactive GDP-bound state. Redistribution of 
RhoGDI to the apical membrane domain complex PC-NHERF-1-ezrin frees RhoA for 
activation by guanine exchange factors. Although sequestration of RhoGDI is not dependent 
on the interaction of PC and NHERF-1 (but does depend on ezrin), activation of RhoA 
requires NHERF-1 association with PC’s C-terminal DTHL motif (Fig. 7).  
A recent study corroborates and extends this finding by showing that the PC-NHERF-ezrin 
ternary complex also regulates activation of Rac1 (a Rho-family member) by a mechanism 
whereby the N-terminal PDZ1 domain of NHERF-1 recruits the Rho guanine nucleotide 
exchange factor 7 (ARHGEF7) to this complex via ARHGEF7’s C-terminal ENTL (a PDZ-
binding motif) (Fig. 7) (Hsu et al., 2010).  Cell motility requires a coordinated reorganization 
of the cytoskeleton, a process regulated in part by Rho-family GTPases. By regulating the 
activity and apical localization of RhoGDI, and ARHGEF7, PC may promote motility in 
some circumstances. Thus, in addition to dramatic morphogenic changes in the apical 
domain of epithelial cells resulting in reduced cell-cell and cell-matrix adhesion, 
inappropriate or unregulated expression of PC may promote cell motility by regulating the 
activity of small GTPases. Although the above studies were conducted in MDCK cells, 
others have shown that Rac1 mediates PC-enhanced invasion and motility of PC3 and MCF7 
cells (Sizemore et al., 2007).  
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Fig. 7. Podocalyxin enhances activation of Rho-family GTPases by sequestration of RhoGDI 
and recruitment of a guanine exchange factor (ARHGEF7) to a PC-ezrin-NHERF complex 
assembled at membrane domains. 
6.2.2 ERK and PI3K pathways 
Forced expression of PC in MCF7 and PC3 cells induces ezrin-dependent activation of the 
Akt and Erk1/2 pathways (Sizemore et al., 2007). Moreover, activation of PI3K/Akt and 
Erk1/2 is required for PC-enhanced invasiveness of MCF7 and PC3. Invasiveness of PC-
expressing cells was mediated in part by expression and secretion of matrix 
metalloproteinase -9 (MMP-9) and MMP-1, which in turn, required expression of ezrin and 
activation of PI3K and Erk1/2 (Sizemore et al., 2007).  
Tyrosine phosphorylation of ezrin at central residue (Y353) has been shown to bind the 
regulatory subunit (p85) of class I PI3Ks and this association, in turn, induces activation of 
the PI3K pathway (Fievet et al., 2004; Gautreau et al., 1999). In addition, tyrosine 
phosphorylation of a residue (Y567) in ezrin’s C-terminal domain disrupts the active 
conformation of ezrin and promotes intermolecular interactions with F-actin and other 
binding partners (Brambilla & Fais, 2009). Expression of PC in MCF7 and PC3 enhances 
phosphorylation of both the PI3K-activating Y353 and Y567 residues of ezrin (perhaps by 
Src-family kinases) (Sizemore et al., 2007). Activation of Erk1/2 via ezrin may be more 
indirect, proceeding through activation of Rho-family GTPases (Sahai and Marshall, 2002). 
6.3 Podocalyxin enhances CXCL12-mediated migration of hematopoietic cells 
CXCL12 (formerly known as stromal derived factor 1 (SDF1)) is a critical chemotatic factor 
for the maintenance of hematopoietic cells in the BM niche and also for the maintenance of 
secondary lymphoid organ architecture. CXCL12 is a ligand for two GPCR chemokine 
receptors, CXCR4 and CXCR7 (reviewed in Teicher and Fricker, 2010).  CXCR4 has a well-
established role in mediating CXCL12 chemotatic cues in cells, whereas CXCR7 does not 
appear to be a competent signalling receptor on its own, but may regulate CXCR4 activity. 
Importantly, CXCR4 and CXCR7 expression or function is dysregulated in many human 
cancers, including (but not limited to) myleloid and lymphoid leukemias and many of the 
carcinomas discussed in this review. Expression or dysregulated signalling of CXCR4 and 
CXCR7 promote the metastasis and survival of cancers to (or within) tissues rich in CXCL12 
(Sun et al., 2010). 
In our efforts to understand the function of PC expression on hematopoietic stem and 
progenitor cells (HSC/Ps), we have used an RNAi approach to knockdown Podxl expression  
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in a mouse myeloid-progenitor, factor dependent cell line, FDCP-1. We have previously 
shown that PC is highly expressed in FDCP-1 and, upon stimulation with interleukin-3 
(IL3), PC is redistributed from a global membrane expression pattern to a polarized 
membrane domain that also recruits NHERF-1 (Tan et al., 2006). Recently, we have found 
that silencing Podxl in FDCP-1 inhibits CXCL12-mediated migration (manuscript 
submitted). In corroboration of this finding, primary hematopoietic cells derived from Podxl-
/- fetal liver (day 15.5 embryos) also display impaired migration to CXCL12 in an in vitro 
assay. Although we have not yet uncovered the molecular mechanisms underlying PC-
enhanced migration to CXCL12, we have found that stimulation of FDCP-1 (or mouse fetal 
liver) with stem cell factor induces enhanced surface exposure CXCR4 that then becomes 
distributed with PC to a common polarized membrane domain. This distribution suggests 
that PC and CXCR4 can physically associate at the cell surface. Indeed, CXCR4 can be co-
precipitated with PC antibodies under some conditions (unpublished observations). We 
hypothesize that PC, as exemplified by the related sialomucins CD34, PSGL-1 and CD164 
(endolyn) (Forde et al., 2007; Veerman et al., 2007; Blanchet et al, 2011), has an active role in 
hematopoietic cell migration and tissue homing by stabilizing or enhancing chemokine 
receptor signalling. Although we currently favour a mechanism by which PC associates 
with, and physically stabilizes, CXCR4 at a polarized membrane domain, PC may also 
enhance intracellular CXCR4 signalling pathways including activation of Rho GTPase, PI3K 
and Erk1/2 (see §6.2.1 & 6.2.2). 
6.4 Stabilization of the glucose-3-transporter (GLUT3) 
GLUT3 (SLC2A3), one of 14 glucose transporter family members (GLUT1-14), was originally 
identified as a neuronal-specific glucose transporter but is also expressed in other tissues with 
high-energy demands, including cancer cells (Macheda et al., 2005; Thorens & Mueckler, 2010; 
Cairns et al., 2011). PC was recently found to form a stable complex with GLUT3 in human 
embryonal carcinoma cells (Tera-1 and NCITT) since GLUT3 can be co-precipitated from cell 
lysates using PNA or anti-PC antibody (and, inversely, podocalyxin is co-precipitated with 
anti-GLUT3 antibody) (Schopperle et al., 2010). Suppression of PODXL expression via siRNA 
also reduced GLUT3 protein concentrations in NCITT (Schopperle et al., 2010) – suggesting 
that PC may stabilize GLUT3 protein or regulate expression of GLUT3. 
7. Conclusion 
7.1 Podocalyxin drives tissue morphogenesis and promotes tumour invasion, 
metastasis and survival  
By expressing full-length and mutant forms of PC in cancer cell lines and assessing cell 
morphology, apical targeting of proteins, motility and invasion, we and others begun to assign 
specific functions to PC structural domains. An emerging theme is that the highly charged and 
glycosylated extracellular domain of PC helps to define the apical domain of epithelial sheets – 
perhaps purely by a biophysical charge- and steric-repulsion mechanism. However, when 
overexpressed at high concentration, PC can drive epithelial cell morphogenesis and trigger 
intracellular cytoskeletal rearrangements that support formation of microvilli (possibly as a 
mechanism for coping with apical domain expansion), reduce adhesion to extracellular matrix 
and adjacent cells; and, facilitate cell shedding from monolayers. In this way, overexpression 
of PC promotes EMT-independent tumour invasion and metastasis. Table 3 summarizes these 
and other tumour-promoting mechanisms regulated by PC. 
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Mechanism of invasion & metastasis Podocalyxin functions in tumour cells 
Morphogenesis & detachment from 
basement membranes 
 Inter- and intra-cellular biophysical charge-repulsion 
 Recruitment/sequestration of cortical actin complexes to 
apical membrane and weakening of ECM adhesion 
 Exclusion of integrins from the apical domain 
Invasion of surrounding tissue 
 PC association with collagen at leading edge 
 Recruitment and apical localization of cortactin and 
induced expression and secretion of MMPs at the leading 
edge 
High motility 
 Enhanced CXCL12/CXCR4 axis signalling and 
chemotaxis  
 Activation and localization of Rho-family GTPases 
 Enhanced activation of PI3K and ERK1/2 
Homing and to distant tissue sites 
 Potential E/L-selectin ligand in some tumours  
 CXCL12/CXCR4 mediated engraftment and survival in 
secondary tissue 
Adherence-independent survival 
 Enhanced activation of PI3K/Akt and Erk 1/2 pathways 
 Promote expression/stabilization of GLUT3 
Table 3. Mechanisms of podocalyxin-enhanced tumour progression. 
Although the initial apical domain-sorting of PC may be, in part, a property of extracellular 
or transmembrane determinants, the prevailing evidence suggests that association of PC’s 
intracellular domain with ezrin and NHERF-1/2 (and consequently to F-actin and the 
cytoskeleton), is responsible for fine-tuning or stabilizing the apical localization of PC in 
epithelial cells. In other words, NHERF-1/2 and ezrin enhance the efficient and functionally 
appropriate apical targeting of PC. Subsequently, PC engagement of NHERF-1/2 and ezrin 
can serve to nucleate signalling complexes at these apical domains and regulate the spatial 
signaling by these complexes. For example, NHERF-1/2 and ezrin promote activation of 
Rho-family GTPases, and cooperate to promote the activation of the Erk1/2 and PI3K/Akt 
pathways. In addition, since NHERF-1/2 and ezrin themselves have multiple protein-
protein interaction domains, regulatory motifs and associate with numerous signalling 
intermediates (Table 2), the potential function of PC in regulating apical signalling events is 
likely much more extensive. By recruiting NHERF-1/2 and ezrin, PC has a role in the 
temporal and spatial localization of signalling intermediates that contribute to enhanced 
invasion, motility and adhesion-independent survival of tumor cells. 
PC recruits cortactin, to apical membrane domains by an as-yet undetermined mechanism 
that may be independent of NHERF-1/2 and ezrin. Cortactin is commonly localized to 
leading edge tumour cell protrusions, called invadopodia, where it promotes invasive 
functions, including the secretion of matrix metalloproteinase and regulates cortical actin 
rearrangements that promote cell morphogenesis and motility. In addition, by stabilizing 
GLUT3, PC may not only support a metabolic switch to oxygen-poor glycolysis, but also 
alter downstream glycosylation machinery. Both of these events have the potential to 
promote adhesion-independent survival and metastasis of tumour cells. 
Since some sialomucins, including endolyn (CD164) and PSGL-1, have been implicated in 
enhanced chemokine-mediated migration of hematopoietic cells (Forde et al., 2007; Veerman 
et al., 2007), we have also examined PC’s role in mediating the migration of hematopoietic 
precursor cells to specific chemokines. Our preliminary work suggests that PC promotes the  
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Fig. 8. Summary of podocalyxin-mediated molecular mechanisms promoting tumour 
growth, invasion, migration and adhesion-independent survival. 
migration of hematopoietic cells and possibly tumor cells to CXCL12, perhaps by stabilizing 
the surface expression (and localization) of CXCR4. Thus, upregulation of PC on tumors 
may herald the acquisition of a great capacity for migration to CXCL12 rich tissues 
including bone, lung and brain. 
7.2 Podocalyxin poorly differentiated tumours and promotes EMT and EMT-
independent invasion and metastasis in human cancers 
Evaluation of PC expression in human cancers, coupled with tumour characteristics and 
patient outcome data, reveals four cancer-indication “profiles” where high PC expression in 
primary tumours provides important diagnostic and prognostic information (Table 4 (I-III)) 
or polymorphisms in PODXL exons predicts cancer risk and tumour aggressiveness (Table 
4, IV). These tumour-expression profiles, combined with in vitro and in vivo mechanistic 
studies, support the contention that PC promotes tumour invasion and metastases. In some 
human cancers, high PC expression is commonly detected in poorly differentiated, 
anaplastic tumour subtypes but not in lower grade tumours that retain differentiation 
markers and characteristics (Profile I). PC expression is also commonly detected in testicular 
cancer, a germ-line tumour. In these cases, PC may serve as a marker of immature or “de-
differentiated” cells that have undergone EMT or retained a more primitive gene expression 
profile (perhaps derived from tissue stem cells). However, a causal link between PC 
expression and tumour progression and invasion is not proven in these profile I cancers. 
Nevertheless, drawing on in vitro studies, we hypothesize that PC may contribute to (but not 
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initiate) the invasive or aggressive tumour phenotype in some of these cancers. For this 
reason, cancers of this type may benefit by the advent of PC diagnostics as a supplemental 
approach to the staging or differential diagnosis of primary tumor origin. We note that the 
clinical application of PC expression profiling for cancer diagnostics is achievable with 
existing reagents and technology, requiring only a concerted effort of validation. 
 
Profile I.  Podocalyxin is commonly expressed in high-grade or poorly differentiated tumours 
 Thyroid carcinoma (undifferentiated) 
 Pancreatic ductal/ampullary carcinoma 
 Small-cell lung carcinoma 
 Acute myeloid and lymphoid leukemia and myeloid sarcoma 
 Anaplastic nephroblastoma 
 Testicular cancer (germ cell) 
 Malignant astrocytoma 
Profile II.  Podocalyxin is overexpressed in rare subsets of highly aggressive tumours and predicts 
poor prognosis 
 Breast carcinoma 
 Ovarian carcinoma 
 Renal cell carcinoma 
Profile III.  PC expression as potential serum marker but clinical significance expression profile is 
undetermined 
 Testicular cancer 
 Colon cancer (cell line) 
Profile IV. PODXL polymorphisms and SNPs associated with cancer risk and tumor aggressiveness 
 Prostate carcinoma 
Table 4. Podocalyxin expression profiles in human cancer. 
In some cancers, PC overexpression in rare, highly aggressive tumour subtypes clearly 
correlates with enhanced tumour invasion, risk of metastasis and poor patient outcome 
(Profile II). In these cases, we propose that PC expression directly promotes EMT-
independent invasion and metastases. We anticipate that further detailed analyses of 
aggressive tumor sub-types, especially for epithelial carcinomas, will expand the examples 
of rare, PC expressing, aggressive tumours in profile II. For instance: Because forced 
expression of PC in a prostate tumour cell line enhances invasive and migration potential, 
and PC is expressed in malignant prostate tumours (but not primary or normal adjacent 
tumours) (Fig. 4), we predict that a subset of high PC-expressing primary prostate tumours 
will display high risk of metastases. Evaluation of PC expression in primary tumours of 
profile II has the most value for prognostic assessment and the design of treatment and 
surveillance strategy. Furthermore, we hope that it will be possible to exploit PC expression 
in these indications for the development of targeted adjuvant therapies (see §7.3). 
The detection of PC (or fragments) in serum may also provide a noninvasive biomarker of 
tumour progression or treatment progress in some cancers (profile III). The case is strongest 
for testicular cancer where serum PC (aka GCTM-2 or TRA-1-60) may be a more robust 
marker than current “gold-standard” biomarkers used in testicular cancer diagnostics.  We 
suspect that cancers that commonly express high levels of PC (profile I) may also shed PC 
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fragments into serum and continued research will likely confirm PC’s utility as diagnostic 
serum marker. If so, PC detection in serum may be a generally useful for detecting disease 
or monitoring tumour progression and treatment efficacy. 
Finally, genetic profiling of the PODXL locus reveals a fourth profile where polymorphisms 
in PODXL exons are associated with increase prostate cancer risk and tumor aggressiveness 
(Table 4 (IV)). Although it will be important to evaluate whether these genetic markers 
correlate with PC expression in prostate cancer or have any role in PC’s functions in these 
tumours, screening for PODXL polymorphisms has potential theranostic applications in 
designing treatment strategies for prostate cancer patients.  
7.3 Podocalyxin-targeted therapies for the treatment of metastatic cancer 
There are several challenges to overcome in the development of PC-targeted adjuvant 
therapies for the treatment of high-risk primary tumours or oncolytic treatment of systemic 
cancers. First, we do not yet know if the high PC expression detected on primary tumours in 
the case of aggressive breast, renal cell and ovarian carcinoma is maintained on metastatic 
tumour cells or following engraftment at a secondary tissue site. However, evaluation of PC 
expression in breast and ovarian carcinoma cell lines, many of which were derived from 
metastatic tumours, suggests that PC expression might be a common feature of metastatic 
breast and ovarian cancer  – especially, basal-type breast carcinomas (Fig. 1). Second, any 
PC-targeted therapies must carefully consider potential renal and vascular toxicity since PC 
is highly expressed on glomerular podocytes and on most vasculature. Fortunately, there 
are several examples of uniquely modified, tumour-specific forms of PC. These provide 
feasible targets for antibody-based drugs that are either directly oncolytic or block PC-
mediated functions without affecting the function of normal cells. 
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